See more : M.Yochananof and Sons (1988) Ltd (YHNF.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Valeo Pharma Inc. (VPHIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valeo Pharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Okta, Inc. (OKTA) Income Statement Analysis – Financial Results
- China Southern Airlines Company Limited (CHKIF) Income Statement Analysis – Financial Results
- Simulated Environment Concepts, Inc. (SMEV) Income Statement Analysis – Financial Results
- JMC Electronics Co., Ltd. (6552.TW) Income Statement Analysis – Financial Results
- China Aviation Oil (Singapore) Corporation Ltd (G92.SI) Income Statement Analysis – Financial Results
Valeo Pharma Inc. (VPHIF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.valeopharma.com
About Valeo Pharma Inc.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 53.91M | 27.75M | 13.56M | 7.47M | 6.58M | 4.38M | 1.28M | 985.71K |
| Cost of Revenue | 40.83M | 21.46M | 9.60M | 6.09M | 5.18M | 3.55M | 747.09K | 2.35M |
| Gross Profit | 13.08M | 6.28M | 3.96M | 1.38M | 1.40M | 832.97K | 530.40K | -1.37M |
| Gross Profit Ratio | 24.26% | 22.64% | 29.17% | 18.49% | 21.30% | 19.01% | 41.52% | -138.68% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 126.26K | 0.00 |
| General & Administrative | 22.56M | 18.81M | 13.31M | 3.32M | 3.04M | 2.98M | 2.84M | 1.10M |
| Selling & Marketing | 6.59M | 6.09M | 2.89M | 2.12M | 2.01M | 236.53K | 133.75K | 72.75K |
| SG&A | 29.15M | 24.90M | 16.19M | 5.45M | 5.05M | 3.22M | 2.98M | 1.01M |
| Other Expenses | 1.15M | 0.00 | 123.00K | 198.00K | 253.00K | 147.04K | 50.77K | 0.00 |
| Operating Expenses | 30.31M | 25.39M | 16.65M | 5.68M | 5.14M | 3.26M | 3.14M | 1.01M |
| Cost & Expenses | 71.14M | 46.86M | 26.25M | 11.77M | 10.31M | 6.81M | 3.89M | 3.36M |
| Interest Income | 3.72M | 173.00K | 1.00K | 1.00K | 0.00 | 816.00 | 368.00 | 114.17K |
| Interest Expense | 13.79M | 6.46M | 1.36M | 598.00K | 110.00K | 173.85K | 102.42K | 0.00 |
| Depreciation & Amortization | 2.63M | 1.42M | 743.00K | 424.00K | 135.00K | 44.47K | 40.12K | 38.56K |
| EBITDA | -11.39M | -17.56M | -11.86M | -3.74M | -3.41M | -2.33M | -2.55M | -2.34M |
| EBITDA Ratio | -21.13% | -63.28% | -87.47% | -49.44% | -51.85% | -53.13% | -199.81% | -237.24% |
| Operating Income | -17.23M | -19.60M | -12.94M | -4.12M | -3.55M | -2.37M | -2.59M | -2.38M |
| Operating Income Ratio | -31.96% | -70.66% | -95.45% | -55.11% | -53.90% | -54.15% | -202.95% | -241.15% |
| Total Other Income/Expenses | -10.58M | -7.32M | -1.42M | -644.00K | 122.00K | 28.00K | -1.86M | 460.53K |
| Income Before Tax | -27.81M | -26.92M | -14.23M | -4.76M | -3.62M | -2.40M | -4.50M | -1.92M |
| Income Before Tax Ratio | -51.58% | -97.03% | -104.99% | -63.73% | -54.96% | -54.78% | -352.25% | -194.43% |
| Income Tax Expense | 0.00 | -1.17M | 1.48M | 796.00K | 326.00K | 36.72K | -881.21K | -640.00K |
| Net Income | -27.81M | -25.75M | -14.23M | -4.76M | -3.62M | -2.44M | -3.62M | -1.28M |
| Net Income Ratio | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% | -55.62% | -283.27% | -129.50% |
| EPS | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| EPS Diluted | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| Weighted Avg Shares Out | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
| Weighted Avg Shares Out (Dil) | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
Valeo Pharma launches non-brokered private placement of up to 4,000 unsecured non-convertible debentures units at a price of $1,000
Valeo Pharma launches non-brokered private placement of up to 4,000 unsecured non-convertible debentures units at a price of $1,000 each
Valeo Pharma enters into LOI with pan-Canadian Pharmaceutical Alliance over Redesca and Redesca HP to prevent and treat thromboembolic disorders
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP®
Valeo Pharma shares get a boost as it unveils deal with Novartis on two Health Canada approved asthma therapies
Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada
Valeo Pharma boosts revenue by 76% in 4Q, off the back of several new commercial products
Valeo Pharma Announces Major Addition to its Senior Management Team
Source: https://incomestatements.info
Category: Stock Reports